ReviewNutrients2016
The Intestinal Microbiota in Metabolic Disease.
Review in Nutrients, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03441802 (Gut Microbiota as a Novel Therapeutic Target for Prevention of Cardiovascular Diseases in Obese and Non-obese Adult Subjects), which is not on this map. Cited by 155 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gut Microbiota as a Novel Therapeutic Target for Prevention of Cardiovascular Diseases in Obese and Non-obese Adult Subjects
Who cites it
155 citing papers in PubMed, 1 synthesis or guideline pooled it, 279 citations in OpenAlex.
- Effects of GLP-1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review.The FEBS journal · 2026Pooled it
- Trial
- Trial
- Gut microbiota profiles in Korean children with growth hormone deficiency: a case-control study.Clinical and experimental pediatrics · 2026Article
- Immune dysregulation and gut microbiota: Connection to health and disease development.Neural regeneration research · 2026Article
- Synergistic potential of probiotics and bacteriophages in combating multidrug-resistant microbial infections: A novel therapeutic strategy for the post-antibiotic era.New microbes and new infections · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- From diet to hypothalamic dysfunction: Neuroanatomical and hormonal integration of the microbiota-hypothalamus-adipose tissue axis.Reviews in endocrine & metabolic disorders · 2026Review
- Review
- Trauma and Hemorrhage Lead to An Elevation in Fecal Hort-Chain Fatty Acids.Shock (Augusta, Ga.) · 2026Article
- Targeted regulation of adipose tissue macrophages from an immunometabolic perspective: a novel therapeutic approach for obesity-related metabolic disorders.Frontiers in immunology · 2026Review
- Article
- Changes in gut microbiota before and after treatment in patients with primary hypothyroidism.Open life sciences · 2026Article
- Shengxian decoction modulates gut microbiota and microbial metabolism in rats with chronic heart failure.Frontiers in microbiology · 2026Article
- Transcriptome profiles of peripheral blood mononuclear cells differentiate male adolescents with non-alcoholic fatty liver disease from healthy peers.World journal of hepatology · 2025Article
- Application of edible fungi in gut microbiota regulation.NPJ science of food · 2025Review
- Polysaccharides fromNutrients · 2025Review
- Intestinal bacteria translocation promotes β-cell dysfunction in DIO mice.Scientific reports · 2025Article
- Temporal Dynamics of Fecal Microbiome and Short-Chain Fatty Acids in Sows from Early Pregnancy to Weaning.Animals : an open access journal from MDPI · 2025Article
- The advantages ofFuture microbiology · 2025Review
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut bacteria exert beneficial and harmful effects in metabolic diseases as deduced from the comparison of germfree and conventional mice and from fecal transplantation studies. Compositional microbial changes in diseased subjects have been linked to adiposity, type 2 diabetes and dyslipidemia. Promotion of an increased expression of intestinal nutrient transporters or a modified lipid and bile acid metabolism by the intestinal microbiota could result in an increased nutrient absorption by the host. The degradation of dietary fiber and the subsequent fermentation of monosaccharides to short-chain fatty acids (SCFA) is one of the most controversially discussed mechanisms of how gut bacteria impact host physiology. Fibers reduce the energy density of the diet, and the resulting SCFA promote intestinal gluconeogenesis, incretin formation and subsequently satiety. However, SCFA also deliver energy to the host and support liponeogenesis. Thus far, there is little knowledge on bacterial species that promote or prevent metabolic disease. Clostridium ramosum and Enterococcus cloacae were demonstrated to promote obesity in gnotobiotic mouse models, whereas bifidobacteria and Akkermansia muciniphila were associated with favorable phenotypes in conventional mice, especially when oligofructose was fed. How diet modulates the gut microbiota towards a beneficial or harmful composition needs further research. Gnotobiotic animals are a valuable tool to elucidate mechanisms underlying diet-host-microbe interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.